Lack of prognostic value of epidermal growth factor receptor in a series of 229 T1/T2, N0/N1 breast cancers, with well defined prognostic parameters
The prognostic value of epidermal growth factor receptor (EGF-R) was prospectively assessed in a series of 229 clinical T1-T2, N0-N1 breast carcinomas diagnosed between May 1987 and October 1989. EGF-R expression was determined by measuring the specific Bmax of 125I EGF to tumor plasma membrane prep...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 1994, Vol.29 (3), p.265-270 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 270 |
|---|---|
| container_issue | 3 |
| container_start_page | 265 |
| container_title | Breast cancer research and treatment |
| container_volume | 29 |
| creator | BOLLA, M CHEDIN, M COLONNA, M MARRON-CHARRIERE, J ROSTAING-PUISSANT, B PASQUIER, D PANH, M. H WINCKEL, P CHAMBAZ, E. M |
| description | The prognostic value of epidermal growth factor receptor (EGF-R) was prospectively assessed in a series of 229 clinical T1-T2, N0-N1 breast carcinomas diagnosed between May 1987 and October 1989. EGF-R expression was determined by measuring the specific Bmax of 125I EGF to tumor plasma membrane preparations. Tumor with a Bmax > or = 3 fmol/mg of protein were considered positive with regard to EGF-R expression. With a median follow-up of 34 months, the 3-year overall and disease-free survivals are respectively 92% and 88% for EGF-R < or = 3, and 91% and 86% EGF-R > 3 fmol, showing no significant difference, even when comparing axillary lymph node status. We did not succeed in finding an EGF-R cut-off value which might be significant in univariate analysis. Multivariate analysis of our data indicates that pT (p = 0.001), pN (p = 0.04), and Scarff-Bloom grade (p = 0.04) are the only significant predictors of disease-free survival among the parameters investigated in this study. |
| doi_str_mv | 10.1007/BF00666480 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76618239</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76618239</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-95b15c98c14d48e4fbe2e79cbd6eb3bcbc561e98f27f5b91165eda5d483f06433</originalsourceid><addsrcrecordid>eNpNkctOHDEQRa0oCAaSTfZIXkRZIJqp6ofdXhIUHtKIbCbrlu0uE0O_Yvcwyn_wwfGIEWFVpaqjW1e3GPuCcIEAcvn9GkAIUdbwgS2wkkUmc5Qf2QJQyEzUII7YcYyPAKAkqEN2WEOpSgEL9rLS9omPjk9hfBjGOHvLn3W3od2MJt9S6HXHH8K4nX9zp-08Bh7I0rRr_MA1jxQ8xR2f54qvcbnOz_k9LO-Rm0A6ztzqwVKI53zrk8iWuo635PxA7fuzkw66pzmBn9iB012kz_t6wn5d_1hf3Warnzd3V5erzBaIc6Yqg5VVtcWyLWsqnaGcpLKmFWQKY42tBJKqXS5dZRSiqKjVVWILB6IsihP27VU3ufizoTg3vY822dMDjZvYSCGwzguVwLNX0IYxxkCumYLvdfjbIDS7FzT_X5Dg073qxvTUvqH7zNP-636vo9WdCykdH9-wEiqJeV38A1vLjeA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76618239</pqid></control><display><type>article</type><title>Lack of prognostic value of epidermal growth factor receptor in a series of 229 T1/T2, N0/N1 breast cancers, with well defined prognostic parameters</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>BOLLA, M ; CHEDIN, M ; COLONNA, M ; MARRON-CHARRIERE, J ; ROSTAING-PUISSANT, B ; PASQUIER, D ; PANH, M. H ; WINCKEL, P ; CHAMBAZ, E. M</creator><creatorcontrib>BOLLA, M ; CHEDIN, M ; COLONNA, M ; MARRON-CHARRIERE, J ; ROSTAING-PUISSANT, B ; PASQUIER, D ; PANH, M. H ; WINCKEL, P ; CHAMBAZ, E. M</creatorcontrib><description>The prognostic value of epidermal growth factor receptor (EGF-R) was prospectively assessed in a series of 229 clinical T1-T2, N0-N1 breast carcinomas diagnosed between May 1987 and October 1989. EGF-R expression was determined by measuring the specific Bmax of 125I EGF to tumor plasma membrane preparations. Tumor with a Bmax > or = 3 fmol/mg of protein were considered positive with regard to EGF-R expression. With a median follow-up of 34 months, the 3-year overall and disease-free survivals are respectively 92% and 88% for EGF-R < or = 3, and 91% and 86% EGF-R > 3 fmol, showing no significant difference, even when comparing axillary lymph node status. We did not succeed in finding an EGF-R cut-off value which might be significant in univariate analysis. Multivariate analysis of our data indicates that pT (p = 0.001), pN (p = 0.04), and Scarff-Bloom grade (p = 0.04) are the only significant predictors of disease-free survival among the parameters investigated in this study.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/BF00666480</identifier><identifier>PMID: 8049460</identifier><identifier>CODEN: BCTRD6</identifier><language>eng</language><publisher>Dordrecht: Springer</publisher><subject>Analysis of Variance ; Biological and medical sciences ; Breast Neoplasms - metabolism ; Breast Neoplasms - therapy ; Carcinoma - metabolism ; Carcinoma - therapy ; Combined Modality Therapy ; Epidermal Growth Factor - metabolism ; ErbB Receptors - metabolism ; Female ; Follow-Up Studies ; Gynecology. Andrology. Obstetrics ; Humans ; Mammary gland diseases ; Medical sciences ; Middle Aged ; Prognosis ; Prospective Studies ; Survival Rate ; Tumors</subject><ispartof>Breast cancer research and treatment, 1994, Vol.29 (3), p.265-270</ispartof><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-95b15c98c14d48e4fbe2e79cbd6eb3bcbc561e98f27f5b91165eda5d483f06433</citedby><cites>FETCH-LOGICAL-c311t-95b15c98c14d48e4fbe2e79cbd6eb3bcbc561e98f27f5b91165eda5d483f06433</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,4026,27930,27931,27932</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4057128$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8049460$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BOLLA, M</creatorcontrib><creatorcontrib>CHEDIN, M</creatorcontrib><creatorcontrib>COLONNA, M</creatorcontrib><creatorcontrib>MARRON-CHARRIERE, J</creatorcontrib><creatorcontrib>ROSTAING-PUISSANT, B</creatorcontrib><creatorcontrib>PASQUIER, D</creatorcontrib><creatorcontrib>PANH, M. H</creatorcontrib><creatorcontrib>WINCKEL, P</creatorcontrib><creatorcontrib>CHAMBAZ, E. M</creatorcontrib><title>Lack of prognostic value of epidermal growth factor receptor in a series of 229 T1/T2, N0/N1 breast cancers, with well defined prognostic parameters</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><description>The prognostic value of epidermal growth factor receptor (EGF-R) was prospectively assessed in a series of 229 clinical T1-T2, N0-N1 breast carcinomas diagnosed between May 1987 and October 1989. EGF-R expression was determined by measuring the specific Bmax of 125I EGF to tumor plasma membrane preparations. Tumor with a Bmax > or = 3 fmol/mg of protein were considered positive with regard to EGF-R expression. With a median follow-up of 34 months, the 3-year overall and disease-free survivals are respectively 92% and 88% for EGF-R < or = 3, and 91% and 86% EGF-R > 3 fmol, showing no significant difference, even when comparing axillary lymph node status. We did not succeed in finding an EGF-R cut-off value which might be significant in univariate analysis. Multivariate analysis of our data indicates that pT (p = 0.001), pN (p = 0.04), and Scarff-Bloom grade (p = 0.04) are the only significant predictors of disease-free survival among the parameters investigated in this study.</description><subject>Analysis of Variance</subject><subject>Biological and medical sciences</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - therapy</subject><subject>Carcinoma - metabolism</subject><subject>Carcinoma - therapy</subject><subject>Combined Modality Therapy</subject><subject>Epidermal Growth Factor - metabolism</subject><subject>ErbB Receptors - metabolism</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Survival Rate</subject><subject>Tumors</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkctOHDEQRa0oCAaSTfZIXkRZIJqp6ofdXhIUHtKIbCbrlu0uE0O_Yvcwyn_wwfGIEWFVpaqjW1e3GPuCcIEAcvn9GkAIUdbwgS2wkkUmc5Qf2QJQyEzUII7YcYyPAKAkqEN2WEOpSgEL9rLS9omPjk9hfBjGOHvLn3W3od2MJt9S6HXHH8K4nX9zp-08Bh7I0rRr_MA1jxQ8xR2f54qvcbnOz_k9LO-Rm0A6ztzqwVKI53zrk8iWuo635PxA7fuzkw66pzmBn9iB012kz_t6wn5d_1hf3Warnzd3V5erzBaIc6Yqg5VVtcWyLWsqnaGcpLKmFWQKY42tBJKqXS5dZRSiqKjVVWILB6IsihP27VU3ufizoTg3vY822dMDjZvYSCGwzguVwLNX0IYxxkCumYLvdfjbIDS7FzT_X5Dg073qxvTUvqH7zNP-636vo9WdCykdH9-wEiqJeV38A1vLjeA</recordid><startdate>1994</startdate><enddate>1994</enddate><creator>BOLLA, M</creator><creator>CHEDIN, M</creator><creator>COLONNA, M</creator><creator>MARRON-CHARRIERE, J</creator><creator>ROSTAING-PUISSANT, B</creator><creator>PASQUIER, D</creator><creator>PANH, M. H</creator><creator>WINCKEL, P</creator><creator>CHAMBAZ, E. M</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1994</creationdate><title>Lack of prognostic value of epidermal growth factor receptor in a series of 229 T1/T2, N0/N1 breast cancers, with well defined prognostic parameters</title><author>BOLLA, M ; CHEDIN, M ; COLONNA, M ; MARRON-CHARRIERE, J ; ROSTAING-PUISSANT, B ; PASQUIER, D ; PANH, M. H ; WINCKEL, P ; CHAMBAZ, E. M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-95b15c98c14d48e4fbe2e79cbd6eb3bcbc561e98f27f5b91165eda5d483f06433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Analysis of Variance</topic><topic>Biological and medical sciences</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - therapy</topic><topic>Carcinoma - metabolism</topic><topic>Carcinoma - therapy</topic><topic>Combined Modality Therapy</topic><topic>Epidermal Growth Factor - metabolism</topic><topic>ErbB Receptors - metabolism</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Survival Rate</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BOLLA, M</creatorcontrib><creatorcontrib>CHEDIN, M</creatorcontrib><creatorcontrib>COLONNA, M</creatorcontrib><creatorcontrib>MARRON-CHARRIERE, J</creatorcontrib><creatorcontrib>ROSTAING-PUISSANT, B</creatorcontrib><creatorcontrib>PASQUIER, D</creatorcontrib><creatorcontrib>PANH, M. H</creatorcontrib><creatorcontrib>WINCKEL, P</creatorcontrib><creatorcontrib>CHAMBAZ, E. M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BOLLA, M</au><au>CHEDIN, M</au><au>COLONNA, M</au><au>MARRON-CHARRIERE, J</au><au>ROSTAING-PUISSANT, B</au><au>PASQUIER, D</au><au>PANH, M. H</au><au>WINCKEL, P</au><au>CHAMBAZ, E. M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lack of prognostic value of epidermal growth factor receptor in a series of 229 T1/T2, N0/N1 breast cancers, with well defined prognostic parameters</atitle><jtitle>Breast cancer research and treatment</jtitle><addtitle>Breast Cancer Res Treat</addtitle><date>1994</date><risdate>1994</risdate><volume>29</volume><issue>3</issue><spage>265</spage><epage>270</epage><pages>265-270</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><coden>BCTRD6</coden><abstract>The prognostic value of epidermal growth factor receptor (EGF-R) was prospectively assessed in a series of 229 clinical T1-T2, N0-N1 breast carcinomas diagnosed between May 1987 and October 1989. EGF-R expression was determined by measuring the specific Bmax of 125I EGF to tumor plasma membrane preparations. Tumor with a Bmax > or = 3 fmol/mg of protein were considered positive with regard to EGF-R expression. With a median follow-up of 34 months, the 3-year overall and disease-free survivals are respectively 92% and 88% for EGF-R < or = 3, and 91% and 86% EGF-R > 3 fmol, showing no significant difference, even when comparing axillary lymph node status. We did not succeed in finding an EGF-R cut-off value which might be significant in univariate analysis. Multivariate analysis of our data indicates that pT (p = 0.001), pN (p = 0.04), and Scarff-Bloom grade (p = 0.04) are the only significant predictors of disease-free survival among the parameters investigated in this study.</abstract><cop>Dordrecht</cop><pub>Springer</pub><pmid>8049460</pmid><doi>10.1007/BF00666480</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 1994, Vol.29 (3), p.265-270 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76618239 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Analysis of Variance Biological and medical sciences Breast Neoplasms - metabolism Breast Neoplasms - therapy Carcinoma - metabolism Carcinoma - therapy Combined Modality Therapy Epidermal Growth Factor - metabolism ErbB Receptors - metabolism Female Follow-Up Studies Gynecology. Andrology. Obstetrics Humans Mammary gland diseases Medical sciences Middle Aged Prognosis Prospective Studies Survival Rate Tumors |
| title | Lack of prognostic value of epidermal growth factor receptor in a series of 229 T1/T2, N0/N1 breast cancers, with well defined prognostic parameters |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T10%3A54%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lack%20of%20prognostic%20value%20of%20epidermal%20growth%20factor%20receptor%20in%20a%20series%20of%20229%20T1/T2,%20N0/N1%20breast%20cancers,%20with%20well%20defined%20prognostic%20parameters&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=BOLLA,%20M&rft.date=1994&rft.volume=29&rft.issue=3&rft.spage=265&rft.epage=270&rft.pages=265-270&rft.issn=0167-6806&rft.eissn=1573-7217&rft.coden=BCTRD6&rft_id=info:doi/10.1007/BF00666480&rft_dat=%3Cproquest_cross%3E76618239%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76618239&rft_id=info:pmid/8049460&rfr_iscdi=true |